fbpx

Pioneering Off‑the‑Shelf, Allogeneic T‑Cell Immunotherapies

Mission to transform the lives of patients with serious medical conditions through pioneering science, teamwork and a commitment to excellence

About Us

Robust T‑Cell Immunotherapy Pipeline

Four Strategic Priorities

  • Tab-cel® (tabelecleucel)
  • ATA188
  • ATA2271 & ATA3271
  • ATA3219
View Pipeline

Patient Stories

“I learned how to cultivate wonder about life’s simple moments because I didn’t know how many moments I had left.”
Doug
“Don’t give up. That’s the main thing.”
Ayden
“I have always been very aware of the preciousness of life and that it is something we cannot take for granted.”
Jessica
“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.”
Ola
Doug Ayden Jessica Ola
View Patient Stories
Doug

Patient Stories

“I learned how to cultivate wonder about life’s simple moments because I didn’t know how many moments I had left.”
Doug
Ayden

Patient Stories

“Don’t give up. That’s the main thing.”
Ayden
Jessica

Patient Stories

“I have always been very aware of the preciousness of life and that it is something we cannot take for granted.”
Jessica
Ola

Patient Stories

“I am who I am because of my disability. People read my story and say, ‘You are a role model to me.’ Hearing that from others is what drives me forward.”
Ola
View Patient Stories
World-Class T‑Cell Manufacturing

World-Class T‑Cell Manufacturing

Flexibility to produce multiple T‑cell and CAR T immunotherapies

Dedicated, expandable ATOM (Atara T‑Cell Operations & Manufacturing) facility in Thousand Oaks, CA

View Manufacturing

Latest News

September 14, 2020

Atara Biotherapeutics To Present Clinical Data in Epstein‑Barr Virus‑Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID‑LPD and PID‑LPD) from Tab‑Cel® Expanded Access Program in e‑Poster at ESMO 2020 Virtual Congress

View Press Release View All Press Releases View Press Release
September 11, 2020

Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188

View Press Release View All Press Releases View Press Release
September 08, 2020

Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next‑Generation Autologous Mesothelin‑Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors

View Press Release View All Press Releases View Press Release

Follow Atara Biotherapeutics on LinkedIn to stay up-to-date on the latest developments and pursuit of our mission to transform the lives of patients with serious medical conditions through pioneering science, teamwork and a commitment to excellence.
Linkedin

Follow Us